Trupanion (TRUP) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 delivered strong results with total revenue up 16% year-over-year to $314.8 million and subscription revenue up 20% to $208.6 million, driven by both existing and new pet enrollments.
Net loss narrowed to $5.9 million ($0.14 per share) from $13.7 million ($0.33 per share) in Q2 2023, reflecting improved operating leverage.
Adjusted operating income grew 48% year-over-year to $24.8 million, with subscription segment AOI up 63%.
Free cash flow reached $4 million in Q2 2024, the highest Q2 since going public, and adjusted EBITDA improved to $7.4 million from $(3.2) million in Q2 2023.
Pet acquisition spend was disciplined, with 64,300 new pets acquired at a 37% IRR.
Financial highlights
Total revenue: $314.8 million, up 16% year-over-year; subscription revenue: $208.6 million, up 20% year-over-year.
Net loss: $5.9 million, improved from $13.7 million loss in prior year; net loss per share improved to $(0.14) from $(0.33).
Free cash flow: $4 million, a $12.1 million improvement year-over-year.
Cash and short-term investments: $277.2 million at quarter end; $15 million available under credit facility.
Subscription business contributed 66% of total revenue; other business 34%.
Outlook and guidance
Full-year 2024 revenue guidance raised to $1,263–$1,279 million (15% growth at midpoint); subscription revenue expected at $850–$858 million (20% growth at midpoint).
Adjusted operating income guidance raised to $108–$115 million (33% growth at midpoint).
Q3 2024 revenue expected at $319–$324 million (12% growth at midpoint); Q3 subscription revenue projected at $217M–$219M.
Subscription margin expected to reach 15% in Q4.
Capital resources and liquidity are considered sufficient for the next 12 months; additional financing may be explored for strategic opportunities.
Latest events from Trupanion
- Strong growth, data-driven innovation, and new products position the company for market expansion.TRUP
47th Annual Raymond James Institutional Investor Conference2 Mar 2026 - Low market penetration and strong recurring revenue signal major growth potential.TRUP
Investor presentation2 Mar 2026 - 2026 guidance highlights pricing-led growth, margin expansion, and broader customer acquisition.TRUP
BofA Securities Animal Health Summit26 Feb 2026 - Revenue up 12% to $1.44B, net income $19.4M, strong cash flow and subscription growth.TRUP
Q4 202512 Feb 2026 - Margin expansion, strong retention, and capital surplus drive disciplined growth and innovation.TRUP
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Sustainable growth driven by vet channel, margin recovery, and international expansion.TRUP
Investor Day 202420 Jan 2026 - Q3 2024 saw 15% revenue growth, margin expansion, and improved free cash flow and guidance.TRUP
Q3 202417 Jan 2026 - Q1 2025 saw 12% revenue growth, higher margins, and improved retention with raised guidance.TRUP
Q1 202526 Dec 2025 - 2025 will see renewed marketing investment, high retention, and continued tech-driven growth.TRUP
Raymond James & Associates’ 46th Annual Institutional Investors Conference 202523 Dec 2025